The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label randomized, multicenter, phase II study on neoadjuvant treatment  with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to positron emission tomography (PET) value modification in patients with early stage HER2-positive breast cancer (AVATAXHER): Design description.
Alexandre Cochet
No relevant relationships to disclose
Khaldoun Kerrou
No relevant relationships to disclose
Jean-Marc A. Nabholtz
No relevant relationships to disclose
Florent Cachin
No relevant relationships to disclose
Jean-Yves Pierga
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Laurence Champion
No relevant relationships to disclose
Jean-Marc Ferrero
No relevant relationships to disclose
Jacques Darcourt
No relevant relationships to disclose
Thierry Petit
No relevant relationships to disclose
Khalil Bourahla
No relevant relationships to disclose
Philippe Bougnoux
No relevant relationships to disclose
Jean-Louis Baulieu
No relevant relationships to disclose
Pierre-Francois Dupre
No relevant relationships to disclose
Pierre-Yves Salaun
No relevant relationships to disclose
Thomas Denis Bachelot
No relevant relationships to disclose
Thomas Mognetti
No relevant relationships to disclose
David Emmanuel Coeffic
Consultant or Advisory Role - Roche
Honoraria - Roche
Nathalie Mesnard
Employment or Leadership Position - Roche
Bruno P. Coudert
Consultant or Advisory Role - P Fabre; Roche; Sanofi
Honoraria - Boehringer Ingelheim; Lilly; Roche
Alina Berriolo-Riedinger
No relevant relationships to disclose